Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrolizumab in moderate to severe active ulcerative colitis (LAUREL)
NCT02165215Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2014
- Primary completion
- Apr 2020
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of Etrolizumab in ulcerative colitis (UC), sponsored by Roche. Started Aug 2014; status: completed.
02
Drugs
Etrolizumab
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT02165215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02165215.